Prof Wiedermann - January presentation in SF, page-28

In paul hoopers most recent interview he gave he stated in order for big pharma to do the deal/takeover on phase 1 data alone then the data has to be very good.
Axel Hoos reported more deals/takeovers are now being done very early on in the preclinical trials concerning immune oncology drugs.
In days of old big pharma were not doing the deal until the release of phase 3 data.
It is high risk for big pharma to do the deal/takeover just on phase 1 data as phase 2 and phase 3 trials
have a high risk of not meeting the required end points.
It is forecast that the immune oncology market will be worth 100 billion by 2025.
It keeps rising each year.
B cell vaccines are the next generation immuno oncology drugs.
If the data is good and the vaccines get to market then the pd1 inhibitors will become obsolete.
Big pharma especially Merck with its pd1 inhibitor keytruda,Bristol Myers and Squib with its pd1 inhibitor opdivo will be watching imugenes trial data with great interest.
Who ever moves first will then have the monopoly on the B cell vaccines.
There are vast fortunes to be made by big pharma on acquiring this technology.